Notice of AGM
Updated : 17:24
MGC Pharmaceuticals Ltd.
Notice of AGM
16 November 2022
ASX, LSE: MXC
MGC Pharmaceuticals Limited ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of plant inspired medicines, is pleased to announce that the board will be webcasting the Company's upcoming Annual General Meeting (AGM) to be held at 9:00am GMT on the 24th November 2022 via the Investor Meet Company platform.
In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform, and are therefore encouraged to submit their votes via proxy, per the instructions in the Notice of Meeting.
Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform up until 9am the day before the AGM or submitted at any time during the AGM itself.
Investors can sign up to Investor Meet Company for free and add to meet MGC PHARMACEUTICALS LIMITED via:
https://www.investormeetcompany.com/mgc-pharmaceuticals-limited/register-investor
Investors who already follow MGC PHARMACEUTICALS LIMITED on the Investor Meet Company platform will automatically be invited.
--Ends--
Authorised for release by the Chairman, for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 | UK Broker Turner Pope Andy Thacker +44 203 657 0050 |
UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.